

<b>Reference number(s)</b>
3000-A

## **SPECIALTY GUIDELINE MANAGEMENT**

### **JETREA (ocriplasmin intravitreal injection)**

#### **POLICY**

##### **I. INDICATIONS**

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

##### FDA-Approved Indication

Jetrea is indicated for the treatment of symptomatic vitreomacular adhesion.

All other indications are considered experimental/investigational and not medically necessary.

##### **II. CRITERIA FOR INITIAL APPROVAL**

##### **Vitreomacular adhesion**

Authorization of 90 days for a single dose (for each eye) may be granted for treatment of symptomatic vitreomacular adhesion.

##### **III. REFERENCES**

1. Jetrea [package insert]. Iselin, NJ: ThromboGenics, Inc; February 2017.